These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29039849)

  • 21. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.
    Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T;
    Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics.
    Marksteiner J; Oberacher H; Humpel C
    J Alzheimers Dis; 2019; 68(2):583-589. PubMed ID: 30814361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease.
    Huynh K; Lim WLF; Giles C; Jayawardana KS; Salim A; Mellett NA; Smith AAT; Olshansky G; Drew BG; Chatterjee P; Martins I; Laws SM; Bush AI; Rowe CC; Villemagne VL; Ames D; Masters CL; Arnold M; Nho K; Saykin AJ; Baillie R; Han X; Kaddurah-Daouk R; Martins RN; Meikle PJ
    Nat Commun; 2020 Nov; 11(1):5698. PubMed ID: 33173055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.
    Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C
    Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.
    Wang HF; Tan L; Cao L; Zhu XC; Jiang T; Tan MS; Liu Y; Wang C; Tsai RM; Jia JP; Yu JT;
    J Alzheimers Dis; 2016; 51(1):227-36. PubMed ID: 26836176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology.
    González-Domínguez R; Sayago A; Fernández-Recamales Á
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1071():75-92. PubMed ID: 28189423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease.
    Wood PL; Medicherla S; Sheikh N; Terry B; Phillipps A; Kaye JA; Quinn JF; Woltjer RL
    J Alzheimers Dis; 2015; 48(2):537-46. PubMed ID: 26402017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel method for early diagnosis of Alzheimer's disease based on pseudo Zernike moment from structural MRI.
    Gorji HT; Haddadnia J
    Neuroscience; 2015 Oct; 305():361-71. PubMed ID: 26265552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).
    Cairns NJ; Perrin RJ; Franklin EE; Carter D; Vincent B; Xie M; Bateman RJ; Benzinger T; Friedrichsen K; Brooks WS; Halliday GM; McLean C; Ghetti B; Morris JC; ;
    Neuropathology; 2015 Aug; 35(4):390-400. PubMed ID: 25964057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic disorder in Alzheimer's disease.
    Poddar MK; Banerjee S; Chakraborty A; Dutta D
    Metab Brain Dis; 2021 Jun; 36(5):781-813. PubMed ID: 33638805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
    Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
    J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances from metabolomics and lipidomics application in alzheimer's disease inspiring drug discovery.
    Cuperlovic-Culf M; Badhwar A
    Expert Opin Drug Discov; 2020 Mar; 15(3):319-331. PubMed ID: 31619081
    [No Abstract]   [Full Text] [Related]  

  • 36. Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment.
    Martínez-Torteya A; Treviño V; Tamez-Peña JG
    Biomed Res Int; 2015; 2015():961314. PubMed ID: 26106620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.
    Graham SF; Chevallier OP; Elliott CT; Hölscher C; Johnston J; McGuinness B; Kehoe PG; Passmore AP; Green BD
    PLoS One; 2015; 10(3):e0119452. PubMed ID: 25803028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
    González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
    Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
    Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.